Výsledky vyhledávání

Fatal cyclophosphamide cardiomyopathy: its clinical course and treatment

Autor: C K, Lee, G S, Harman, R J, Hohl, R D, Gingrich

Publikováno v: Bone marrow transplantation. 18(3)

Acute decompensating cardiomyopathy induced by cyclophosphamide is usually irreversible. To investigate the clinical course and the outcome of therapy, 13 patients (1.7%) with grade III acute cardiomyopathy and hypotension who were treated with ablat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::149aef9e9ca6e722243a53cf4be09263
https://pubmed.ncbi.nlm.nih.gov/8879620

Zobrazit plný text záznamu

A randomized, double-blind comparison of single-dose and divided multiple-dose dolasetron for cisplatin-induced emesis

Autor: G. S. Harman, William F. Hahne, Kevin Ryan, John D. Hainsworth, Michael B. Cramer, George A. Omura

Publikováno v: Cancer chemotherapy and pharmacology. 38(4)

Purpose: Intravenous dolasetron has been shown to be an effective antiemetic agent in patients receiving high-dose cisplatin-containing chemotherapy. Previous studies have suggested that 1.8 mg/kg is an optimal dose for achieving control of emesis an

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10ff8436e6e5565f6577ff5f204811db
https://pubmed.ncbi.nlm.nih.gov/8674154

Zobrazit plný text záznamu

Allogeneic bone marrow transplantation for acute myelogenous leukemia, acute lymphocytic leukemia, and multiple myeloma following preparation with busulfan and cyclophosphamide (BuCy2)

Autor: E A, Copelan, J C, Biggs, J, Szer, J M, Thompson, P, Crilley, I, Brodsky, J L, Klein, N, Kapoor, G S, Harman, B R, Avalos

Publikováno v: Seminars in oncology. 20(4 Suppl 4)

The combination of busulfan (Bu) and cyclophosphamide (Cy) has been found to be effective preparative therapy for patients treated with allogeneic bone marrow transplantation (BMT). We developed the BuCy2 regimen, which contains a lower dose of cyclo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::311e356c34a51d34d3157a996cb891f3
https://pubmed.ncbi.nlm.nih.gov/8342074

Zobrazit plný text záznamu

Pilot trial of prophylactic ursodiol to decrease the incidence of veno-occlusive disease of the liver in allogeneic bone marrow transplant patients

Autor: J H, Essell, J M, Thompson, G S, Harman, R D, Halvorson, M J, Snyder, N S, Callander, D J, Clement

Publikováno v: Bone marrow transplantation. 10(4)

Ursodiol is a hydrophilic, non-hepatotoxic bile salt indicated for the medical treatment of cholesterol gallstones. This pilot study explored the use of prophylactic ursodiol in an attempt to decrease the incidence and severity of veno-occlusive dise

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::8737dbe9028a4e3cf9594436561f1584
https://pubmed.ncbi.nlm.nih.gov/1422493

Zobrazit plný text záznamu

Phase I clinical and pharmacokinetic trial of flavone acetic acid

Autor: John G. Kuhn, Daniel D. Von Hoff, G. S. Harman, David H. Boldt, J. B. Craig, Gary N. Clark, A. Kathleen Havlin, Geoffrey R. Weiss, Rowena Schwartz, Jim M. Koeller

Publikováno v: Journal of the National Cancer Institute. 83(2)

Flavone acetic acid is a synthetic benzopyrone derivative with an unknown mechanism of action. Thirty-eight patients (30 men and 8 women) were treated once a week for 4 weeks every 5 weeks with doses of flavone acetic acid ranging from 0.33 to 12.5 g

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bdab195f5f152bc42e9fd5c054302c25
https://pubmed.ncbi.nlm.nih.gov/1703237

Zobrazit plný text záznamu

Phase I evaluation of crisnatol (BWA770U mesylate) on a monthly extended infusion schedule

Autor: Judy N. Turner, Richard L. Tuttle, J. Scott Luther, Daniel D. Von Hoff, Patrick W. Cobb, William Wargin, John G. Kuhn, Dennis A. Tweedy, J. B. Craig, G. S. Harman, Jim M. Koeller, Geoffrey R. Weiss, John K. Whisnant, V. Sol Lucas, K. Havlin

Publikováno v: Selective cancer therapeutics. 7(2)

Crisnatol is an arylmethylaminopropanediol derivative that has shown promise as an antitumor agent in preclinical testing. In a phase I trial using a monthly six-hour infusion schedule the recommended dose for future phase II trials was found to be 3

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15a6408cf67a86f50cf6fca9e1706f1a
https://pubmed.ncbi.nlm.nih.gov/1754731

Zobrazit plný text záznamu

Some Current Trends and Issues in the Governance of Australian Colleges of Advanced Education

Autor: C. Selby Smith, G. S. Harman

Publikováno v: Australian Journal of Education. 20:129-148

This paper attempts to isolate some key current trends and issues of particular importance for the governance of Australian CAEs and explores a small number of their implications for governance at institutional level, at State level and at national l

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d547c388531d789f56afb8b9fe85a343
https://doi.org/10.1177/000494417602000201

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání